The race for advanced weight-loss treatments is intensifying with the emergence of new oral medications. Eli Lilly's orforglipron, a daily pill, has shown promising results in clinical trials, demonstrating greater effectiveness than current oral semaglutide drugs.
Participants in a recent trial experienced an average body weight loss of six to eight percent with orforglipron, compared to four to five percent with semaglutide. Furthermore, 28 to 44 percent of participants on orforglipron achieved a weight loss of 10 percent or more, a significantly higher rate than those on semaglutide. The drug also showed improved blood sugar reduction in patients with type 2 diabetes.
Orforglipron is designed for increased accessibility and convenience, requiring no food or water restrictions. Eli Lilly aims for orforglipron to compete with existing market leaders. While not yet approved by the FDA, the drug is under regulatory review. If approved, pricing for US patients is anticipated to range from $149 to $399 per month, before insurance coverage.
However, the trial did report higher adverse effects, primarily gastrointestinal issues, leading some participants to discontinue treatment. Researchers note that longer-term safety and sustained effectiveness remain key areas for future study.